Regulations.gov document
Migraine: Developing Drugs for Preventive Treatment Guidance for Industry
Other · FDA-2022-D-1729 · posted Jun 2, 2023
Key facts
| Document ID | FDA-2022-D-1729-0006 |
|---|---|
| Title | Migraine: Developing Drugs for Preventive Treatment Guidance for Industry |
| Document type | Other |
| Subtype | Guidance |
| Agency | FDA |
| Docket | FDA-2022-D-1729 |
| Posted | Jun 2, 2023 |
| Comment period opens | Jun 2, 2023 |
| Comments due | Aug 2, 2023 |
At a glance
- No Open for comment
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: